

advancing quality through innovation

JUNE 4-8, 2010 | MCCORMICK PLACE | CHICAGO, ILLINOIS



Call for Abstracts

SUBMISSION DEADLINE:
JANUARY 12, 2010, 11:59 PM (EASTERN STANDARD TIME)

2010 ASCO ANNUAL MEETING: ADVANCING QUALITY THROUGH INNOVATION

ASCO is now accepting abstracts to be considered for presentation or publication at the 46th Annual Meeting in Chicago, Illinois. This year's meeting will focus on Advancing Quality through Innovation and will provide an opportunity to discuss the latest innovations in research, quality, practice, and technology in cancer. ASCO encourages the submission of abstracts of 300 to 350 words in the following areas:

- **Research:** focusing on new therapies to prevent, detect, and manage cancer to ultimately advance patient care and deliver progress
- **Quality:** highlighting methods to improve care, mitigate disparities, ensure access to treatments, and maintain an adequate workforce for future patients
- **Technology:** developing new and novel technologies to educate and help the entire oncology practice operate more efficiently

Make your contribution to this premier oncology event by submitting your original research abstract today. To submit an abstract, visit the official online Abstract Submitter program at www.asco.org/cfa.

Abstract Submission Deadline: January 12, 2010, 11:59 PM Eastern Standard Time (EST)



ANNUAL MEETING AND ABSTRACT SUBMISSION KEY DATES

DATE	DESCRIPTION
September 2009	Registration and housing opens exclusively for members.
December 2009	General registration and housing opens. Annual Meeting program information—in the form of “sneak peeks” of session titles and faculty—is made available at www.asco.org/chicago2010 .
January 12, 2010, 11:59 PM (EST)	Deadline for submission of abstracts for the 2010 Annual Meeting.
January 19, 2010	Deadline for submission of abstract exception applications.
March 2010	The Scientific Program Committee meets to select abstracts.
Late March 2010	Letters of notification are sent by e-mail to First Authors regarding the decisions of the Scientific Program Committee.
March 29, 2010	Deadline for submission of updated Late-breaking Abstracts.
April 2010	First Authors of Late-breaking Abstracts are notified of final decisions regarding selection of abstracts. The online Annual Meeting Planner, which offers express or customized meeting itineraries, is available at www.asco.org/chicago2010 .
April 9, 2010	Deadline to withdraw or to make changes to an abstract.
April 28, 2010	Deadline for early registration.
May 20, 2010	Abstracts released on ASCO.org.
June 4-8, 2010	46th ASCO Annual Meeting at McCormick Place, Chicago, Illinois.



“For a half century the ASCO meeting has been the gathering place for clinical scientists to share and critique each other’s works and results. The more than 2,000 abstracts presented—all peer-reviewed by experts in the field—represent the very best in clinical and translational science results and are intended to either change practice today or provide insight into future practice-changing studies.”

- Daniel F. Hayes, MD

Chair, 2009-2010 Scientific Program Committee

ABSTRACT SUBMISSION: WHAT'S NEW IN 2010?

As you prepare to submit your abstract, please keep in the mind the following changes to the 2010 abstract submission process:

- ASCO has a new electronic abstract submission system. Feedback is welcome and can be sent to abstracts@asco.org.
- A \$60 administrative fee, payable at the time of submission, will be associated with all abstract submissions.
- E-mail addresses are now required for all co-authors, as well as for the First Author. A search feature will be provided to find e-mail addresses for ASCO members. Any changes to member information can be made by visiting the MyASCO section of ASCO.org or by contacting ASCO Member Services at 888-282-2552, 703-299-0158, or via e-mail at membermail@asco.org. Please note that member information cannot be updated within the Abstract Submitter.
- First Authors of registered clinical trials will be asked to enter the name of the clinical trial registry and the trial registration number.
- A separate Coauthor Disclosure Form has been created for abstracts that report on clinical trials. Coauthor Disclosure Forms can be downloaded at www.asco.org/cfa.

CHANGES TO THE CONFLICT OF INTEREST DISCLOSURE PROCESS

PRESENTATION RESTRICTIONS FOR FIRST AUTHORS EMPLOYED BY ACCME-DEFINED COMMERCIAL INTERESTS

If the First Author is employed by a commercial interest as defined by the Accreditation Council for Continuing Medical Education (ACCME) and the abstract is selected for presentation in an Oral Abstract Session, an alternate presenter who does not have a relevant employment relationship must be named.

For detailed information regarding the ASCO Conflict of Interest Policy, see page 11.

ADDITIONAL QUESTIONS FOR CLINICAL TRIAL ABSTRACTS THAT DO NOT IDENTIFY A PRINCIPAL INVESTIGATOR

Clinical trial abstracts that do not identify a principal investigator will be asked to answer additional questions.

For more detailed information about ASCO's disclosure requirements, including ASCO's definition of "principal investigator," see page 11.

ASCO HAS CREATED A NEW CALL FOR ABSTRACTS WEBSITE


Visit www.asco.org/cfa for the most detailed information on changes to the submission process, submission requirements, the abstract selection process, and Annual Meeting Abstract Policies. There you will also find quick links to the Abstract Submitter, Coauthor Disclosure Forms, and Frequently Asked Questions.

TRIALS IN PROGRESS POSTER SESSION

The 2010 Annual Meeting will include a new session, the Trials in Progress Poster Session, designed exclusively to facilitate awareness of and dialogue about open, ongoing clinical trials. This session will encourage discussions of new clinical research and the exchange of ideas on clinical trial design.

Abstracts submitted to the Trials in Progress Poster Session should not include results. **These abstracts will not count as the author's one allowed submission.** The administrative fee will apply to this abstract category, and sponsorship must be attained from an ASCO Active or Active-Junior member, if the author is not an ASCO member. All conflict of interest policies apply. No CME credit will be offered for this session.

For more information on the Trials in Progress Poster Session, visit www.asco.org/cfa.



“Advancing quality through innovation is much of what we do in our professional lives to provide quality cancer care, which is why I’ve chosen it as the theme for the 2010 Annual Meeting. Join us as we present practice-changing results from clinical and translational studies performed around the world.”

- **Douglas W. Blayney, MD**
2009-2010 ASCO President

ABSTRACT PREPARATION AND SUBMISSION

ABSTRACT SUBMISSION CHECKLIST

During the submission process, please keep in mind the following requirements:

- ✓ No more than 10 individual authors may be listed for each abstract. An authoring group may be used to indicate the remaining authors.
- ✓ New this year, e-mail addresses are required for all coauthors, as well as for the First Authors.
- ✓ Conflict of interest disclosure information must be provided for the First Author and for all coauthors. Coauthor Disclosure Forms can be downloaded at www.asco.org/cfa.
- ✓ Submissions must adhere to the biostatistical guidelines (see www.asco.org/cfa) set forth by the Biostatistics Core of the Scientific Program Committee. Although all of the elements are not required, the absence of one or more elements may have a negative effect on the abstract review and placement process.
- ✓ Abstracts may not exceed 2,000 characters (approximately 300 to 350 words). This includes characters used in an abstract title and table.
- ✓ The title should objectively describe the study. Do not refer to study results or conclusions in the title. **ASCO reserves the right to edit conclusive titles.**
- ✓ Do not use proprietary names in the title or body of the abstract. (If necessary, you may include a proprietary name in parentheses directly after the generic name on first use in the body of the abstract.) ASCO reserves the right to replace proprietary names with generic names.
- ✓ A \$60 administrative fee will be charged per abstract submitted. Credit cards will be the only acceptable form of electronic payment.

For more detailed information on these requirements and for additional abstract submission guidelines, visit www.asco.org/cfa.



RESPONSIBILITIES OF THE FIRST AUTHOR

The First Author may submit only ONE abstract as First Author (unless submitting to the Trials in Progress Poster Session; see page 5 for more information).

The First Author must:

- Obtain sponsorship from an ASCO Active or Active-Junior member, if he or she is not an ASCO member. An ASCO Active-Allied member, Associate member, or International Corresponding member may sponsor his or her own abstract but cannot sponsor an abstract for another First Author. An ASCO Affiliate member must obtain sponsorship.
- Verify that, if necessary for the work reported, the clinical research represented in the abstract was approved by an appropriate ethics committee or institutional review board and that, if appropriate to the research, informed consent was obtained for all subjects.
- Verify that all coauthors are aware of the contents of the abstract and support its data.
- Agree, on behalf of all coauthors, to transfer copyright to ASCO.
- Agree to present the abstract if it is selected for presentation at the ASCO Annual Meeting. (This includes being present during the scheduled time of a Poster Session.) If the first author is employed by a commercial interest as defined by ACCME, an alternate presenter who does not have a relevant employment relationship must be named if the abstract is selected for presentation in an Oral Abstract Session.
- Adhere to the ASCO Conflict of Interest Policy (*J Clin Oncol.* 2006;24[3]:519-521) and obtain disclosure information from all coauthors using the appropriate disclosure forms (forms can be downloaded at www.asco.org/cfa).

- Comply with ASCO's conflict of interest management decisions, including the potential for slide review prior to presentation (Oral Abstract Presenters only). **Information on these procedures is available at www.asco.org/conflictinterest.**
- Ensure that all coauthors meet the definition of authorship as stated by the International Committee of Medical Journal Editors (www.icmje.org).
- Convey the Annual Meeting Abstract Policies, summarized on page 10, to all coauthors and the Sponsor(s) of the research. (Abstract policies can be found in their entirety at www.asco.org/cfa).

RESPONSIBILITIES OF THE SPONSOR

An ASCO Active or Active-Junior member may sponsor multiple abstracts; otherwise, a Sponsor may sponsor only one abstract (his or her own abstract).

The Sponsor must:

- Be an ASCO Active, Active-Junior, Active-Allied or International Corresponding,¹ or Associate member² in good standing³
- Verify the contents of the abstract and support its data
- Comply with the Annual Meeting Abstract Policies (summarized on page 10; view the policies in their entirety at www.asco.org/cfa)

¹An ASCO Active-Allied or International Corresponding member may only sponsor his or her own abstract.

²An ASCO Associate member who sponsors his or her own abstract must also obtain a signature from the Training Program Director. (The Training Program Director does not have to be an ASCO member and may sign for more than one Associate member.)

³ASCO members who need to pay their membership dues should visit the MyASCO section of ASCO.org. Members who need to reactivate their membership should contact ASCO Member Services at 888-282-2552 or 703-299-0158.

LATE-BREAKING ABSTRACTS

The ASCO Late-breaking Abstracts Policy allows for the submission of Late-breaking Abstracts **only for randomized phase II and phase III trials for which no preliminary data are available at the time of the abstract submission deadline** (January 12), but for which a preplanned analysis of the primary endpoint is scheduled after that date but before March 29 (deadline for the final, updated Late-breaking Abstract). The policy is not a mechanism to allow for updated data to be submitted later when preliminary data are available by the abstract submission deadline.

At the time of the Scientific Program Committee's initial review of Late-breaking Abstracts (submitted by the January 12 deadline), two decisions are possible:

- **Potential** presentation at an Oral Abstract Session
- Rejection

At the time of the Committee's review of updated Late-breaking Abstracts (after the March 29 deadline), three decisions are possible:

- Presentation at an Oral Abstract Session
- Online publication only in association with the content of the *2010 ASCO Annual Meeting Proceedings*
- Rejection

Note that a decision regarding **potential** presentation **does not guarantee** that the abstract will be selected for presentation or publication after review of updated data. **Final decisions regarding the selection of Late-breaking Abstracts will be made after March 29.**

First Authors of Late-breaking Abstracts have an opportunity to request that the abstract be withdrawn if the Committee deems it acceptable for online publication only.

For information on the essential steps in submitting a Late-breaking Abstract, visit www.asco.org/cfa.

ONLINE-ONLY ABSTRACTS

Abstracts of acceptable quality that are not selected by the ASCO Scientific Program Committee for presentation may be chosen for online publication only, with the full text of the abstracts available online at www.asco.org.

CHANGES TO ABSTRACTS

First Authors may request corrections to rectify errors (i.e., typos, misspellings) within abstract submissions. Requests for changes must be sent by the First Author to abstracts@asco.org. **Updates to original data will not be permitted; changes are permissible only for the correction of errors.** The deadline to submit change requests is **April 9, 2010**.

WITHDRAWAL OF ABSTRACTS

If the First Author wishes to withdraw his or her abstract for any reason, a written request must be submitted by **April 9, 2010**, to the ASCO Scientific Program Committee Chair, c/o ASCO Education, Science, and Professional Development Department, 2318 Mill Road, Suite 800, Alexandria, VA 22314. Requests may also be sent via e-mail to abstracts@asco.org. Any abstract withdrawal requests received after this date will be considered on a case-by-case basis and cannot be assured removal from the *2010 ASCO Annual Meeting Proceedings*. The First Author of a Late-breaking Abstract may request that the abstract be withdrawn if the updated abstract is deemed acceptable for online publication only by the Committee at the time of review (March 29, 2010).

TOPIC CATEGORIES FOR ABSTRACT SUBMISSION

Breast Cancer—Local-Regional and Adjuvant Therapy

Breast Cancer—Metastatic Breast Cancer

Cancer Prevention/Epidemiology

Central Nervous System Tumors

Developmental Therapeutics—Clinical Pharmacology and Immunotherapy

Developmental Therapeutics—Experimental Therapeutics

Gastrointestinal (Colorectal) Cancer

Gastrointestinal (Noncolorectal) Cancer

Genitourinary Cancer

Gynecologic Cancer

Head and Neck Cancer

Health Services Research

Leukemia, Myelodysplasia, and Transplantation

Lung Cancer—Local-Regional and Adjuvant Therapy

Lung Cancer—Metastatic Lung Cancer

Lymphoma and Plasma Cell Disorders

Melanoma/Skin Cancers

Patient and Survivor Care

Pediatric Oncology

Sarcoma

Tumor Biology

ABSTRACT-ASSOCIATED AWARDS

Trainees in the United States and other countries and oncologists from countries with limited resources are eligible for awards in conjunction with submitting an abstract for the Annual Meeting. These awards are offered through The ASCO Cancer Foundation® Grants Program.

Fellows and Junior Faculty: Merit Awards

A limited number of \$1,500 Merit Awards will be given to recognize trainees who submit high-quality abstracts. The award includes complimentary registration for the Annual Meeting and access to Meeting housing reserved for ASCO members.

The First Author must meet all of the following requirements to be considered for a Merit Award:

- Hold a doctoral degree (including but not limited to MD, DO, PharmD, or PhD) or be a doctoral degree candidate at the time of abstract submission
- Be enrolled in an oncology fellowship training program or equivalent training program at the time of abstract submission
- Work in an oncology laboratory or clinical research setting
- Agree to present the abstract at the Annual Meeting
- Provide a letter of support from his or her Training Program Director, indicating eligibility for the award
- Provide a two-page curriculum vitae

International Development and Education Award

The ASCO Cancer Foundation International Development and Education Award (IDEA) provides support for oncologists in developing countries to attend the ASCO Annual Meeting and to visit a cancer center in the United States or Canada. The IDEA program is designed to provide continuing medical education, assist in career development, and help recipients establish strong relationships with leading ASCO members who serve as scientific mentors. Submission of an abstract is preferred criteria (not a requirement) for an IDEA applicant.



Award terms, eligibility requirements, and IDEA application information are available at www.asco.org/idea.

ABSTRACT POLICIES

Upon submission of an abstract, the First Author must agree to the following abstract policies on behalf of all parties involved, including the Sponsor. The First Author is also responsible for communicating these policies to all involved parties. **If any of these policies are violated, the involved abstract may be removed from the Annual Meeting.**

Abstract policies are summarized below; to read the policies in their entirety, visit www.asco.org/cfa.

- 1) **Confidentiality Policy.** Prior to the information being publicly released in conjunction with the Annual Meeting, the First Author, coauthors, and Sponsor of the research may not make the information public or provide it to others who may make it public (such as the news media); publish or present the information or provide it to others who may publish or present it; or use the information for trading in the securities of any issuer or provide it to others who may use it for securities trading purposes.
- 2) **Prior Presentation/Publication Policy.** For a study to be eligible for acceptance into the ASCO Annual Meeting, the contents and conclusions of the abstract must not be presented at any scientific, medical, or educational meeting of 500 registrants or more or be published in a scientific, medical, or educational publication before the Annual Meeting. Exception: An abstract submitted for presentation at the ASCO-cosponsored Breast Cancer, Gastrointestinal Cancers, and Genitourinary Cancers Symposia; Annual Meeting on Molecular Markers in Cancer; or Multidisciplinary Symposium in Thoracic Oncology may also be submitted for presentation at the 2010 ASCO Annual Meeting. Authors are encouraged to provide updated data in the abstract.
- 3) **Press Policy.** Members of the press will honor the confidentiality of all abstracts accepted for the Annual Meeting until the abstracts are publicly released. Authors who are contacted by the news media regarding their study before the information has been made public should contact ASCO before speaking to the press.
- 4) **Abstract Exceptions.** If information from the abstract or study data are disclosed in advance of public release in conjunction with the ASCO Annual Meeting, the abstract will no longer be eligible for inclusion in the Meeting unless an official Abstract Exception applies.



CONFLICT OF INTEREST POLICY AND EXCEPTIONS

In compliance with standards established by the ASCO Conflict of Interest Policy (*J Clin Oncol*. 2006; 24[3]:519-521) and the Accreditation Council for Continuing Medical Education (ACCME), ASCO strives to promote balance, independence, objectivity, and scientific rigor through disclosure of financial and other interests, and identification and management of potential conflicts. According to the Society's Conflict of Interest Policy, the following financial and other relationships must be disclosed: employment or leadership position, advisory role, stock ownership, honoraria, research funding, expert testimony, and other remuneration (*J Clin Oncol*. 2006;24[3]:520).

The ASCO Conflict of Interest Policy requirements apply to all abstract authors. It is the responsibility of the First Author to obtain disclosure information from all coauthors and to provide all disclosure of such interests and relationships through the Abstract Submitter program. Copies of the Disclosure Forms (which can be downloaded at www.asco.org/cfa) can be sent to coauthors for completion and return before submission of the abstract.

Per the ASCO Conflict of Interest Policy Implementation Plan for CME Activities, all Oral Abstract Presenters will be subject to the same disclosure review and management strategies as faculty who participate in ASCO CME activities.

For clinical trials that began accrual on or after April 29, 2004, ASCO's Policy places some restrictions on

the financial relationships of principal investigators (*J Clin Oncol*. 2006;24[3]:521). If a principal investigator holds any restricted relationships, his or her abstract may be ineligible for placement in the 2010 Annual Meeting unless the Ethics Committee grants an exception. Among the circumstances that might justify an exception are that the principal investigator (1) is a widely acknowledged expert in a particular therapeutic area; (2) is the inventor of a unique technology or treatment being evaluated in the clinical trial; or (3) is involved in international clinical oncology research and has acted consistently with recognized international standards of ethics in the conduct of clinical research.

When a principal investigator has restricted relationships, the First Author will be prompted to apply to the Ethics Committee for an exception to the Policy. ASCO will collect information on accrual initiation date, financial relationships of the principal investigator, and National Institutes of Health (NIH) funding upon abstract submission. NIH-funded trials are exempt from the Policy restrictions.

Exception request materials may be uploaded as part of the abstract submission process or e-mailed to coi@asco.org. **The final deadline for submission of exception request materials is January 19, 2010.**

For more information on the ASCO Conflict of Interest Policy, the Conflict of Interest Policy Implementation Plan for CME Activities, the restrictions on principal investigators, and applying for an exception to the Policy, please visit www.asco.org/conflictinterest.

Additional Questions for Clinical Trial Abstracts That Do Not Identify a Principal Investigator

ASCO's Conflict of Interest Policy identifies the principal investigator (PI) of a clinical trial as "the individual with primary responsibility for the development of the protocol, the conduct of the trial, and the interpretation and dissemination of the trial data." Generally, it is expected that these responsibilities will rest with a single individual designated as the principal investigator and having the unique leadership responsibilities described in the Policy.

Identifying a PI is not required for abstract submission. However, First Authors of clinical trial abstracts that do not identify a PI will be asked to respond to additional questions about the individual(s) who completed the responsibilities assigned to the PI under ASCO's Conflict of Interest Policy.

SPONSOR YOUR OWN ABSTRACT

at the 2010 ASCO Annual Meeting



JOIN ASCO AND RECEIVE EXCLUSIVE MEMBERS' ONLY BENEFITS

Membership has its privileges at the ASCO Annual Meeting. All abstracts for the Annual Meeting must be sponsored by an ASCO member. Join today to submit and sponsor an abstract and first author and/or sponsor the work of your colleagues.*

Other meeting related benefits of ASCO membership:

- Save an average of 50%* off the Annual Meeting nonmember registration rates
- Receive advance access to reserve the closest hotels and most sought-after ticketed sessions with Members' Only Housing and Registration

JOIN TODAY to be part of the only professional organization that represents all oncology disciplines. Visit www.asco.org/membership for a comprehensive list of member benefits and download a membership application. Simply mail, fax or e-mail your completed membership application to:

ASCO Member Services

2318 Mill Road, Suite 800 | Alexandria, VA 22314
Fax: (703) 299-0255 | E-mail: membermail@asco.org

For personal service or to learn more about the benefits of ASCO membership, please call ASCO Member Services at (703) 299-0158 or (888) 282-2552.

* Varies by membership category



American Society of Clinical Oncology

Making a world of difference in cancer care